Beactica Therapeutics AB, a Sweden-based precision oncology company, announced on Tuesday that it has signed a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS), one of 27 institutes and centers at the US National Institutes of Health (NIH).

The partnership is aimed at the translation of novel proteolysis-targeting degraders of TEAD under development by Beactica for treatment of cancer.

Under the agreement, NCATS will gain access to proprietary targeted degraders of TEAD from Beactica to evaluate their efficacy in disease-relevant preclinical models. NCATS will also map systematically the drug-combination landscape for selected preclinical candidates by performing a high-throughput drug-combination screen using a collection of about 3,000 oncology-focused, mechanistically annotated drugs.

Dr Per Källblad, Beactica Therapeutics CEO, said, 'We are very pleased to be selected by NCATS and look forward to collaborating with them to maximise the therapeutic potential of our targeted degraders of TEAD. Their extensive expertise and capabilities will accelerate our project's progress, enhancing its potential to positively impact patients.'